Clinical trial
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney…
NCT00126503 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00126503 |
|---|---|
| Title | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer |
| Official title | A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Sorafenib Tosylate, Pharmacological Study, Laboratory Biomarker Analysis |
| Enrollment | 73 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | Aug 4, 2005 |
| Last update posted | Jan 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: